7- O -Malonyl Macrolactin A, a New Macrolactin Antibiotic from Bacillus subtilis Active against Methicillin-Resistant Staphylococcus aureus , Vancomycin-Resistant Enterococci, and a Small-Colony Variant of Burkholderia cepacia-Reference-Cited by-同舟云学术

7- O -Malonyl Macrolactin A, a New Macrolactin Antibiotic from Bacillus subtilis Active against Methicillin-Resistant Staphylococcus aureus , Vancomycin-Resistant Enterococci, and a Small-Colony Variant of Burkholderia cepacia

Published:2006-05 Issue:5 Volume:50 Page:1701-1709
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Romero-Tabarez Magally¹,Jansen Rolf¹,Sylla Marita¹,Lünsdorf Heinrich¹,Häußler Susanne²,Santosa Dwi A.³⁴,Timmis Kenneth N.¹,Molinari Gabriella¹

Affiliation:

1. Division of Microbiology

2. Cell Biology, German Research Centre for Biotechnology, Braunschweig, Germany

3. Department of Soil Science and Land Resource, Faculty of Agriculture, Bogor Agricultural University

4. Indonesian Center for Biodiversity and Biotechnology, Bogor, Indonesia

Abstract

ABSTRACT We report here the discovery, isolation, and chemical and preliminary biological characterization of a new antibiotic compound, 7- O -malonyl macrolactin A (MMA), produced by a Bacillus subtilis soil isolate. MMA is a bacteriostatic antibiotic that inhibits a number of multidrug-resistant gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia . MMA-treated staphylococci and enterococci were pseudomulticellular and exhibited multiple asymmetric initiation points of septum formation, indicating that MMA may inhibit a cell division function.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.50.5.1701-1709.2006

Reference40 articles.

1. Bax, R., N. Mullan, and J. Verhoef. 2000. The millennium bugs—the need for and development of new antibacterials. Int. J. Antimicrob. Agents16:51-59.

2. Vancomycin-Resistant Enterococci

3. Chavers, L. S., S. A. Moser, W. H. Benjamin, S. E. Banks, J. R. Steinhauer, A. M. Smith, C. N. Johnson, E. Funkhouser, L. P. Chavers, A. M. Stamm, and K. B. Waites. 2003. Vancomycin-resistant enterococci: 15 years and counting. J. Hosp. Infect.53:159-171.

4. Choi, S.-W., D.-H. Bai, J.-H. Yu, and C. S. Shin. 2003. Characteristics of the squalene synthase inhibitors produced by a Streptomyces species isolated from soils. Can. J. Microbiol.49:663-668.

5. Craig, W. A., and S. Gudmundsson. 1991. The postantibiotic effect, p. 403-431. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacillus velezensis: a versatile ally in the battle against phytopathogens—insights and prospects;Applied Microbiology and Biotechnology;2024-08-15

2. Whole Genome Sequencing of Bacillus velezensis AMR25, an Effective Antagonist Strain against Plant Pathogens;Microorganisms;2024-07-26

3. Two Strains of Endophytic Bacillus velezensis Carrying Antibiotic-Biosynthetic Genes Show Antibacterial and Antibiofilm Activities Against Methicillin-Resistant Staphylococcus aureus (MRSA);Indian Journal of Microbiology;2024-04-02

4. Macrolactin A Is an Inhibitor of Protein Biosynthesis in Bacteria;2024-02-11

5. A Novel Bacillus Velezensis for Efficient Degradation of Zearalenone;Foods;2024-02-09